| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Transformation Officer
1 company
Lauren Rusckowski Duprey is Chief Transformation Officer at TKPHF. Lauren Rusckowski Duprey's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $8.0M at current prices.
The TKPHF filings lean toward selling, a net 82,121 shares.
Lauren Rusckowski Duprey has 4 Form 4 filings on record from April 2026 to September 2026, all as Chief Transformation Officer at Takeda Pharmaceutical (TKPHF), 2026.
The 4 reported transactions were 2 open-market sales and 2 stock awards.
Counted by filing, the open-market trades come to no purchases and 2 sales worth about $1.5M.
The largest open-market sale was 47,586 shares of TKPHF at an average $17.10 on August 10, 2026, about $814K.
Neither of the two sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.